Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Dollar change +0.70
Percentage change 0.48	%

Held by: IJH VTI VB VXF VBK XBI MDY IBB USMV IJK

Index	-	P/E	40.35	EPS (ttm)	3.64	Insider Own	2.21%	Shs Outstand	98.70M	Perf Week	0.76%
Market Cap	14.77B	Forward P/E	21.51	EPS next Y	6.82	Insider Trans	-16.33%	Shs Float	98.41M	Perf Month	8.08%
Income	369.70M	PEG	2.24	EPS next Q	1.13	Inst Own	92.99%	Short Float	2.67%	Perf Quarter	6.56%
Sales	1.98B	P/S	7.45	EPS this Y	84.12%	Inst Trans	-1.46%	Short Ratio	3.47	Perf Half Y	4.11%
Book/sh	23.72	P/B	6.19	EPS next Y	50.07%	ROA	12.68%	Short Interest	2.63M	Perf Year	46.24%
Cash/sh	12.03	P/C	12.20	EPS next 5Y	18.00%	ROE	18.16%	52W Range	99.36 - 150.39	Perf YTD	11.41%
Dividend Est.	-	P/FCF	24.05	EPS past 5Y	62.04%	ROI	14.01%	52W High	-2.39%	Beta	0.36
Dividend TTM	-	Quick Ratio	2.47	Sales past 5Y	34.77%	Gross Margin	97.09%	52W Low	47.75%	ATR (14)	3.50
Dividend Ex-Date	Dec 29, 1995	Current Ratio	2.52	EPS Y/Y TTM	458.67%	Oper. Margin	23.73%	RSI (14)	63.09	Volatility	2.22% 2.37%
Employees	1400	Debt/Eq	0.23	Sales Y/Y TTM	23.99%	Profit Margin	18.65%	Recom	1.62	Target Price	161.42
Option/Short	Yes / Yes	LT Debt/Eq	0.11	EPS Q/Q	153.10%	Payout	0.00%	Rel Volume	0.98	Prev Close	146.10
Sales Surprise	0.57%	EPS Surprise	-61.75%	Sales Q/Q	22.57%	Earnings	Aug 01 BMO	Avg Volume	757.39K	Price	146.80
SMA20	2.46%	SMA50	5.34%	SMA200	11.83%	Trades		Volume	744,761	Change	0.48%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-24-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$140 → $170
Dec-13-23	Resumed	Citigroup	Neutral	$127
Dec-12-23	Initiated	Deutsche Bank	Buy	$136
Oct-24-23	Resumed	Cantor Fitzgerald	Overweight	$135 → $140
Aug-21-23	Reiterated	Mizuho	Neutral	$112 → $113
Jul-24-23	Upgrade	SVB Securities	Market Perform → Outperform	$115 → $125
Jul-06-23	Upgrade	BMO Capital Markets	Underperform → Market Perform	$91 → $96
May-04-23	Upgrade	Guggenheim	Neutral → Buy	$145
Mar-30-23	Upgrade	Canaccord Genuity	Hold → Buy	$124 → $132
Mar-03-23	Upgrade	Evercore ISI	In-line → Outperform	$130
Feb-03-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$120 → $130
Nov-14-22	Downgrade	Evercore ISI	Outperform → In-line	$140 → $130
Oct-11-22	Initiated	UBS	Buy	$136
Sep-26-22	Initiated	Wells Fargo	Equal Weight	$110
Jun-06-22	Resumed	Jefferies	Buy	$126 → $112
Mar-03-22	Downgrade	Piper Sandler	Overweight → Neutral	$114 → $94
Feb-25-22	Upgrade	Goldman	Neutral → Buy	$115
Jan-18-22	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$122 → $90
Nov-19-21	Initiated	BMO Capital Markets	Underperform	$76
Nov-17-21	Upgrade	JP Morgan	Neutral → Overweight	$124

Show Previous Ratings

Jul-25-24 10:02AM	Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Jul-18-24 08:30AM	Neurocrine Biosciences Launches INGREZZA SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing (PR Newswire)
Jul-12-24 08:38AM	Implied Volatility Surging for Neurocrine Biosciences (NBIX) Stock Options (Zacks)
Jul-11-24 04:01PM	Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial Results (PR Newswire)
Jul-02-24 06:33AM	FDA grants priority review for Neurocrines crinecerfont NDAs (Pharmaceutical Technology)
07:30AM	Loading…
Jul-01-24 07:30AM	Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH (PR Newswire)
Jun-28-24 04:37PM	How Medicare drug price negotiations could hit pharma stocks (Yahoo Finance Video)
Jun-17-24 03:27PM	7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline (InvestorPlace)
Jun-14-24 02:34PM	Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans (Investor's Business Daily)
Jun-03-24 08:01AM	Neurocrine Biosciences Presented CAHtalyst Phase 3 Pediatric and Adult Studies, CAHtalog Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024 (PR Newswire)
07:35AM	Neurocrine Biosciences Announces Publication of Primary CAHtalyst Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine (PR Newswire)
07:30AM	Neurocrine Biosciences Announces Publication of Primary CAHtalyst Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine (PR Newswire)
May-29-24 04:01PM	Neurocrine Biosciences to Participate at Investor Conferences in June (PR Newswire)
May-28-24 04:14PM	Neurocrine Biosciences Announces CEO Succession Plan (PR Newswire)
08:30AM	Neurocrine Biosciences to Present New Phase 3 CAHtalyst Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ENDO 2024 (PR Newswire)
04:05PM	Loading…
May-21-24 04:05PM	Neurocrine Biosciences Announces Publication of Phase 3 KINECT-4 Post Hoc Analysis Demonstrating Clinically Meaningful and Sustained Improvement in Tardive Dyskinesia With Long-Term Use of INGREZZA (valbenazine) Capsules (PR Newswire)
May-16-24 04:47PM	Neurocrine Biosciences Insider Sold Shares Worth $4,138,436, According to a Recent SEC Filing (MT Newswires)
May-14-24 08:30AM	Neurocrine Biosciences Presented Baseline Data from the CAHtalyst Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024 (PR Newswire)
May-09-24 11:51AM	How Neurocrine, An IBD 50 Stock, Is Stacking Up Wins In 2024 And Outperforming Peers (Investor's Business Daily)
11:51AM	How Neurocrine Is Stacking Up Wins In 2024 And Outperforming Peers (Investor's Business Daily)
09:45AM	Neurocrine Biosciences Presents CAHtalyst Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024 (PR Newswire)
08:30AM	Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy Adults (PR Newswire)
02:35AM	Nxera Pharma's partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults (GlobeNewswire)
May-08-24 08:30AM	Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults (PR Newswire)
May-07-24 04:15PM	Neurocrine Biosciences to Present at the BofA Securities 2024 Health Care Conference (PR Newswire)
08:30AM	Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024 (PR Newswire)
May-06-24 08:30AM	Neurocrine Biosciences Supports Tardive Dyskinesia Awareness Week by Advocating for Routine Screening and Monitoring (PR Newswire)
May-04-24 08:00AM	Nvidia Leads Five Stocks Near Buy Points As Market Rally Picks Up Steam (Investor's Business Daily)
May-03-24 01:15PM	Neurocrine Biosciences Presented CAHtalyst Pediatric Study Baseline Characteristics and CAHtalog Registry Data at PES 2024 (PR Newswire)
May-02-24 11:18AM	UBS Raises Price Target on Neurocrine Biosciences to $174 From $165, Maintains Buy Rating (MT Newswires)
03:01AM	Loading…
03:01AM	Neurocrine Biosciences Inc (NBIX) Q1 2024 Earnings Call Transcript Highlights: Robust Growth ... (GuruFocus.com)
01:06AM	Decoding Neurocrine Biosciences Inc (NBIX): A Strategic SWOT Insight (GuruFocus.com)
May-01-24 11:36PM	Q1 2024 Neurocrine Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
09:01PM	Neurocrine Biosciences Inc (NBIX) Q1 2024 Earnings: Strong Revenue Growth and Strategic Advancements (GuruFocus.com)
04:18PM	Why Things Are Looking Up For IBD Stock Of The Day Neurocrine, A Top 1% Biotech (Investor's Business Daily)
11:54AM	NBIX Stock Earnings: Neurocrine Biosciences Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
09:30AM	Neurocrine (NBIX) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
09:04AM	No. 1 Biotech Stock Neurocrine Pops After Its Biggest Moneymaker Snatches Another Win (Investor's Business Daily)
08:31AM	Neurocrine Biosciences Swings to Q1 Adjusted Earnings as Revenue Increases -- Shares Jump Pre-Bell (MT Newswires)
08:15AM	Neurocrine Biosciences (NBIX) Q1 Earnings Miss Estimates (Zacks)
07:18AM	Neurocrine: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Neurocrine Biosciences Reports First Quarter 2024 Financial Results (PR Newswire)
Apr-30-24 05:48PM	REFILE-UPDATE 2-Neurocrine Biosciences' Huntington's disease drug gets FDA approval (April 30) (Reuters)
05:45PM	Neurocrine Gets FDA Approval for Ingrezza Sprinkle Capsules; Shares Rise After-Hours (MT Newswires)
05:31PM	FDA approves Neurocrine Biosciences' Huntington's disease drug (Reuters)
05:12PM	Neurocrine Biosciences Announces U.S. FDA Approval of INGREZZA SPRINKLE (valbenazine) Capsules (PR Newswire)
09:15AM	Curious about Neurocrine (NBIX) Q1 Performance? Explore Wall Street Estimates for Key Metrics (Zacks)
Apr-24-24 10:15AM	Does Neurocrine, The No. 1 Biotech Stock, Have The Next Ketamine On Its Hands? (Investor's Business Daily)
10:01AM	Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
08:30AM	Neurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia Community (PR Newswire)
08:00AM	3 Red-Hot Biotech Rockets Blasting Off in 2024 (InvestorPlace)
Apr-23-24 11:50AM	No. 1 Biotech Stock Neurocrine Launches Higher On Depression Treatment Win (Investor's Business Daily)
07:22AM	Neurocrine scores surprise win with depression drug (BioPharma Dive)
07:00AM	Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder (PR Newswire)
Apr-22-24 11:10AM	10 Best Performing Biotech ETFs in 2024 (Insider Monkey)
Apr-16-24 04:01PM	Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides (GlobeNewswire)
02:30AM	Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568 (GlobeNewswire)
Apr-10-24 04:01PM	Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results (PR Newswire)
Apr-09-24 07:37AM	11 Best Biotech ETFs To Buy (Insider Monkey)
Apr-03-24 08:30AM	Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder (PR Newswire)
Mar-28-24 08:30AM	Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults (PR Newswire)
Mar-24-24 09:19AM	Top 12 Stocks in George Soros' Stock Portfolio (Insider Monkey)
Mar-23-24 08:00AM	S&P 500 Giants Lead Five Stocks Near Buy Points With Fed's Powell A Tailwind (Investor's Business Daily)
Mar-16-24 08:00AM	AI Plays HubSpot, Arista Networks Lead Five Stocks Near Buy Points In Classic Base (Investor's Business Daily)
01:23AM	Neurocrine Biosciences Inc's Chief Regulatory Officer Ingrid Delaet Sells 3,000 Shares (GuruFocus.com)
01:23AM	Director Richard Pops Sells 23,200 Shares of Neurocrine Biosciences Inc (NBIX) (GuruFocus.com)
Mar-15-24 10:00AM	Neurocrine Biosciences Is Pioneering Therapies for Neurological Disorders (GuruFocus.com)
Mar-13-24 01:26AM	Director Richard Pops Sells Shares of Neurocrine Biosciences Inc (NBIX) (GuruFocus.com)
Mar-11-24 04:01PM	Neurocrine Biosciences to Participate at Virtual Investor Conferences in March (PR Newswire)
01:12PM	The $1 Billion Opportunity Driving IBD Stock Of The Day Neurocrine Higher (Investor's Business Daily)
Mar-06-24 04:45PM	3 Cutting-Edge Biotech Stocks Sitting on the Brink of Success (InvestorPlace)
Mar-01-24 12:40AM	Neurocrine Biosciences Inc's Chief Regulatory Officer Ingrid Delaet Sells Company Shares (GuruFocus.com)
Feb-27-24 04:01PM	Neurocrine Biosciences to Participate at Investor Conferences in March (PR Newswire)
Feb-22-24 11:28PM	Director Richard Pops Sells 15,000 Shares of Neurocrine Biosciences Inc (GuruFocus.com)
03:55AM	11 Best Small-Cap Growth Stocks to Invest In (Insider Monkey)
Feb-15-24 11:36PM	Neurocrine Biosciences Inc's Chief Commercial Officer Eric Benevich Sells Company Shares (GuruFocus.com)
Feb-10-24 10:18AM	Wall Street Analysts Just Trimmed Price Targets for These 10 Stocks (Insider Monkey)
12:14AM	Decoding Neurocrine Biosciences Inc (NBIX): A Strategic SWOT Insight (GuruFocus.com)
Feb-09-24 02:23AM	Neurocrine Biosciences Inc's Chief Commercial Officer Eric Benevich Sells Company Shares (GuruFocus.com)
Feb-08-24 09:13AM	Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q4 2023 Earnings Call Transcript (Insider Monkey)
12:20AM	Q4 2023 Neurocrine Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-07-24 09:30AM	Neurocrine (NBIX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
07:33AM	Neurocrine Biosciences Inc (NBIX) Reports Strong Growth in INGREZZA Sales for Q4 and Full Year 2023 (GuruFocus.com)
07:18AM	Neurocrine: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2023 Financial Results and Provides Financial Expectations for 2024 (PR Newswire)
Feb-05-24 09:16AM	Ahead of Neurocrine (NBIX) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics (Zacks)
Feb-02-24 11:02PM	Neurocrine Biosciences Inc CFO Matt Abernethy Sells Company Shares (GuruFocus.com)
Jan-31-24 10:00AM	Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy? (Zacks)
Jan-24-24 11:02PM	Neurocrine Biosciences Inc's Chief Legal Officer Sells Shares (GuruFocus.com)
06:54AM	Neurocrine Biosciences is Under Heavy Accumulation, The One Chart that Matters (FX Empire)
Jan-22-24 09:38AM	Growth Stock Portfolio: 15 Companies with At Least 30% Annual Growth Rates (Insider Monkey)
Jan-17-24 04:16PM	Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2023 Financial Results (PR Newswire)
Jan-12-24 09:35AM	5 High Growth NASDAQ Stocks That Are Profitable (Insider Monkey)
Jan-11-24 09:02PM	Neurocrine Biosciences Inc CEO Kevin Gorman Sells 167,858 Shares (GuruFocus.com)
Jan-10-24 09:24AM	How Neurocrine (NBIX) Stock Stands Out in a Strong Industry (Zacks)
Jan-05-24 02:02AM	Director William Rastetter Sells Shares of Neurocrine Biosciences Inc (NBIX) (GuruFocus.com)
Jan-02-24 04:01PM	Neurocrine Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-26-23 06:56PM	13 High Growth Healthcare Stocks to Buy (Insider Monkey)
07:22AM	Neurocrine (NBIX) Soars 6.0%: Is Further Upside Left in the Stock? (Zacks)
Dec-25-23 08:23PM	3 Stocks at the Forefront of Medical Innovation (InvestorPlace)

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lippoldt Darin	Chief Legal Officer	Jul 16 '24	Option Exercise	79.02	7,004	553,456	46,744	Jul 18 04:41 PM
Delaet Ingrid	Chief Regulatory Officer	Jul 16 '24	Option Exercise	103.52	1,957	202,589	9,064	Jul 18 05:00 PM
ABERNETHY MATT	Chief Financial Officer	Jul 16 '24	Option Exercise	73.60	900	66,240	32,428	Jul 18 04:45 PM
Cooke Julie	Chief Human Resources Officer	Jul 16 '24	Option Exercise	61.82	900	55,638	19,102	Jul 18 05:12 PM
LYONS GARY A	Director	Jul 16 '24	Option Exercise	42.76	930	39,767	119,977	Jul 18 04:54 PM
Lippoldt Darin	Chief Legal Officer	Jul 16 '24	Sale	150.00	7,004	1,050,590	39,740	Jul 18 04:41 PM
Delaet Ingrid	Chief Regulatory Officer	Jul 16 '24	Sale	150.03	2,857	428,627	6,607	Jul 18 05:00 PM
LYONS GARY A	Director	Jul 16 '24	Sale	150.03	930	139,530	119,047	Jul 18 04:54 PM
ABERNETHY MATT	Chief Financial Officer	Jul 16 '24	Sale	150.04	900	135,037	31,528	Jul 18 04:45 PM
Cooke Julie	Chief Human Resources Officer	Jul 16 '24	Sale	150.04	900	135,036	18,202	Jul 18 05:12 PM
Cooke Julie	Chief Human Resources Officer	Jul 01 '24	Option Exercise	61.82	10,000	618,200	28,202	Jul 02 09:36 PM
Delaet Ingrid	Chief Regulatory Officer	Jul 01 '24	Option Exercise	79.02	272	21,493	7,779	Jul 02 09:09 PM
Cooke Julie	Chief Human Resources Officer	Jul 01 '24	Sale	140.19	10,000	1,401,864	18,202	Jul 02 09:36 PM
Delaet Ingrid	Chief Regulatory Officer	Jul 01 '24	Sale	138.11	272	37,566	7,507	Jul 02 09:09 PM
Delaet Ingrid	Chief Regulatory Officer	May 31 '24	Option Exercise	79.02	273	21,572	7,780	Jun 04 04:23 PM
Delaet Ingrid	Chief Regulatory Officer	May 31 '24	Sale	136.55	273	37,278	7,507	Jun 04 04:23 PM
SHERWIN STEPHEN A	Director	May 29 '24	Option Exercise	44.68	40,000	1,787,350	51,504	May 30 04:38 PM
SHERWIN STEPHEN A	Director	May 29 '24	Sale	133.46	40,000	5,338,564	26,504	May 30 04:38 PM
Mercier Johanna	Director	May 17 '24	Option Exercise	0.00	2,100	0	2,100	May 21 04:46 PM
SHERWIN STEPHEN A	Director	May 17 '24	Option Exercise	0.00	4,199	0	26,504	May 21 04:51 PM
LYONS GARY A	Director	May 17 '24	Option Exercise	0.00	2,100	0	119,047	May 21 04:57 PM
Norwalk Leslie V	Director	May 17 '24	Option Exercise	0.00	2,100	0	2,100	May 21 05:06 PM
MORROW GEORGE J	Director	May 17 '24	Option Exercise	0.00	4,199	0	4,199	May 21 05:15 PM
POPS RICHARD F	Director	May 17 '24	Option Exercise	0.00	4,199	0	33,711	May 21 05:27 PM
Sharp Shalini	Director	May 17 '24	Option Exercise	0.00	2,100	0	2,100	May 21 05:35 PM
POPS RICHARD F	Director	May 17 '24	Sale	141.84	2,100	297,860	31,611	May 21 05:27 PM
Sharp Shalini	Director	May 17 '24	Sale	141.90	1,106	156,943	994	May 21 05:35 PM
Norwalk Leslie V	Director	May 17 '24	Sale	141.82	1,106	156,850	994	May 21 05:06 PM
ABERNETHY MATT	Chief Financial Officer	May 15 '24	Option Exercise	73.60	15,000	1,104,000	46,528	May 16 04:40 PM
ABERNETHY MATT	Chief Financial Officer	May 15 '24	Sale	140.24	15,000	2,103,609	31,528	May 16 04:40 PM
ABERNETHY MATT	Chief Financial Officer	May 14 '24	Option Exercise	73.60	15,000	1,104,000	46,528	May 16 04:40 PM
LYONS GARY A	Director	May 14 '24	Option Exercise	42.76	12,500	534,500	129,447	May 16 04:55 PM
ABERNETHY MATT	Chief Financial Officer	May 14 '24	Sale	135.66	15,000	2,034,826	31,528	May 16 04:40 PM
LYONS GARY A	Director	May 14 '24	Sale	135.63	12,500	1,695,370	116,947	May 16 04:55 PM
Delaet Ingrid	Chief Regulatory Officer	May 06 '24	Option Exercise	79.02	273	21,572	7,780	May 08 04:26 PM
Delaet Ingrid	Chief Regulatory Officer	May 06 '24	Sale	140.55	273	38,370	7,507	May 08 04:26 PM
BENEVICH ERIC	Chief Commercial Officer	Apr 15 '24	Option Exercise	81.21	19,818	1,609,431	53,365	Apr 17 05:19 PM
BENEVICH ERIC	Chief Commercial Officer	Apr 15 '24	Sale	133.36	19,818	2,643,020	40,778	Apr 17 05:19 PM
Delaet Ingrid	Chief Regulatory Officer	Apr 01 '24	Option Exercise	79.02	272	21,493	7,779	Apr 03 04:44 PM
Delaet Ingrid	Chief Regulatory Officer	Apr 01 '24	Sale	137.30	272	37,346	7,507	Apr 03 04:44 PM
Delaet Ingrid	Chief Regulatory Officer	Mar 21 '24	Option Exercise	103.52	5,000	517,600	12,507	Mar 25 06:02 PM
Delaet Ingrid	Chief Regulatory Officer	Mar 21 '24	Sale	145.06	5,000	725,320	7,507	Mar 25 06:02 PM
BENEVICH ERIC	Chief Commercial Officer	Mar 14 '24	Option Exercise	80.90	75,000	6,067,628	110,299	Mar 15 05:33 PM
MORROW GEORGE J	Director	Mar 14 '24	Option Exercise	39.79	40,000	1,591,600	20,000	Mar 15 05:25 PM
BENEVICH ERIC	Chief Commercial Officer	Mar 14 '24	Sale	139.38	75,000	10,453,417	40,778	Mar 15 05:33 PM
MORROW GEORGE J	Director	Mar 14 '24	Sale	139.42	40,000	5,576,710	0	Mar 15 05:25 PM
POPS RICHARD F	Director	Mar 13 '24	Option Exercise	42.76	23,200	992,032	52,712	Mar 15 05:19 PM
Delaet Ingrid	Chief Regulatory Officer	Mar 13 '24	Option Exercise	106.02	3,000	318,060	10,507	Mar 15 05:15 PM
POPS RICHARD F	Director	Mar 13 '24	Sale	140.33	23,200	3,255,621	29,512	Mar 15 05:19 PM
Delaet Ingrid	Chief Regulatory Officer	Mar 13 '24	Sale	140.14	3,000	420,419	7,507	Mar 15 05:15 PM
Delaet Ingrid	Chief Regulatory Officer	Mar 11 '24	Option Exercise	106.02	200	21,204	7,707	Mar 12 06:38 PM
POPS RICHARD F	Director	Mar 11 '24	Option Exercise	42.76	100	4,276	29,612	Mar 12 06:47 PM
Delaet Ingrid	Chief Regulatory Officer	Mar 11 '24	Sale	140.00	200	28,000	7,507	Mar 12 06:38 PM
POPS RICHARD F	Director	Mar 11 '24	Sale	140.00	100	14,000	29,512	Mar 12 06:47 PM
Delaet Ingrid	Chief Regulatory Officer	Mar 08 '24	Option Exercise	106.02	1,800	190,836	9,307	Mar 12 06:38 PM
POPS RICHARD F	Director	Mar 08 '24	Option Exercise	42.76	1,700	72,692	31,212	Mar 12 06:47 PM
Delaet Ingrid	Chief Regulatory Officer	Mar 08 '24	Sale	140.03	1,800	252,053	7,507	Mar 12 06:38 PM
POPS RICHARD F	Director	Mar 08 '24	Sale	140.05	1,700	238,078	29,512	Mar 12 06:47 PM
Delaet Ingrid	Chief Regulatory Officer	Feb 29 '24	Option Exercise	79.02	273	21,572	7,780	Feb 29 07:02 PM
Delaet Ingrid	Chief Regulatory Officer	Feb 29 '24	Sale	135.51	273	36,994	7,507	Feb 29 07:02 PM
BENEVICH ERIC	Chief Commercial Officer	Feb 28 '24	Option Exercise	53.67	75,000	4,025,043	93,759	Feb 29 06:55 PM
Delaet Ingrid	Chief Regulatory Officer	Feb 28 '24	Option Exercise	79.02	6,544	517,107	10,007	Feb 29 07:02 PM
BENEVICH ERIC	Chief Commercial Officer	Feb 28 '24	Sale	134.69	75,000	10,101,608	40,616	Feb 29 06:55 PM
Delaet Ingrid	Chief Regulatory Officer	Feb 28 '24	Sale	135.34	6,544	885,638	7,507	Feb 29 07:02 PM
Norwalk Leslie V	Director	Feb 27 '24	Option Exercise	84.95	8,000	679,600	8,000	Feb 29 06:50 PM
Norwalk Leslie V	Director	Feb 27 '24	Sale	135.67	8,000	1,085,388	0	Feb 29 06:50 PM
POPS RICHARD F	Director	Feb 20 '24	Option Exercise	12.98	15,000	194,700	44,512	Feb 22 05:11 PM
POPS RICHARD F	Director	Feb 20 '24	Sale	132.47	15,000	1,987,047	29,512	Feb 22 05:11 PM
GORMAN KEVIN CHARLES	Chief Executive Officer	Feb 13 '24	Option Exercise	39.28	5,090	199,951	512,052	Feb 14 05:17 PM
GORMAN KEVIN CHARLES	Chief Executive Officer	Feb 13 '24	Sale	133.02	2,832	376,700	514,596	Feb 15 05:43 PM
Boyer David W.	Chief Corp. Affairs Officer	Feb 13 '24	Sale	133.07	1,811	240,996	4,895	Feb 15 05:33 PM
Onyia Jude	Chief Scientific Officer	Feb 13 '24	Sale	132.94	1,432	190,371	13,128	Feb 15 05:48 PM
Gano Kyle	Chief Business Development Off	Feb 13 '24	Sale	132.89	1,352	179,674	135,166	Feb 15 05:40 PM
ABERNETHY MATT	Chief Financial Officer	Feb 13 '24	Sale	132.85	1,352	179,612	31,528	Feb 15 05:27 PM
ROBERTS EIRY	Chief Medical Officer	Feb 13 '24	Sale	132.96	1,114	148,122	23,716	Feb 15 05:51 PM
BENEVICH ERIC	Chief Commercial Officer	Feb 13 '24	Sale	133.01	1,098	146,050	40,616	Feb 15 05:29 PM
Lippoldt Darin	Chief Legal Officer	Feb 13 '24	Sale	132.99	1,098	146,028	39,740	Feb 15 05:45 PM
Cooke Julie	Chief Human Resources Officer	Feb 13 '24	Sale	133.04	796	105,902	17,976	Feb 15 05:35 PM
Delaet Ingrid	Chief Regulatory Officer	Feb 13 '24	Sale	133.03	716	95,253	7,507	Feb 15 05:38 PM
GORMAN KEVIN CHARLES	Chief Executive Officer	Feb 08 '24	Sale	134.15	2,274	305,052	506,962	Feb 08 07:21 PM
Cooke Julie	Chief Human Resources Officer	Feb 08 '24	Sale	135.44	1,329	179,995	17,263	Feb 08 07:35 PM
Boyer David W.	Chief Corp. Affairs Officer	Feb 08 '24	Sale	135.41	1,328	179,830	4,895	Feb 08 07:46 PM
ABERNETHY MATT	Chief Financial Officer	Feb 08 '24	Sale	134.21	980	131,529	30,314	Feb 08 07:12 PM
ROBERTS EIRY	Chief Medical Officer	Feb 08 '24	Sale	134.21	980	131,522	22,717	Feb 08 07:28 PM
Gano Kyle	Chief Business Development Off	Feb 08 '24	Sale	134.20	980	131,519	133,952	Feb 08 07:17 PM
BENEVICH ERIC	Chief Commercial Officer	Feb 08 '24	Sale	134.19	980	131,509	39,631	Feb 08 07:15 PM
Lippoldt Darin	Chief Legal Officer	Feb 08 '24	Sale	134.24	911	122,289	38,755	Feb 08 07:25 PM
GORMAN KEVIN CHARLES	Chief Executive Officer	Feb 06 '24	Sale	142.18	3,040	432,218	504,919	Feb 08 07:21 PM
Gano Kyle	Chief Business Development Off	Feb 06 '24	Sale	142.20	1,600	227,522	133,072	Feb 08 07:17 PM
ABERNETHY MATT	Chief Financial Officer	Feb 06 '24	Sale	142.19	1,280	182,000	29,434	Feb 08 07:12 PM
BENEVICH ERIC	Chief Commercial Officer	Feb 06 '24	Sale	142.12	1,280	181,910	38,751	Feb 08 07:15 PM
Cooke Julie	Chief Human Resources Officer	Feb 06 '24	Sale	142.07	1,215	172,617	17,263	Feb 08 07:35 PM
ROBERTS EIRY	Chief Medical Officer	Feb 06 '24	Sale	142.24	1,121	159,446	21,837	Feb 08 07:28 PM
Lippoldt Darin	Chief Legal Officer	Feb 06 '24	Sale	142.17	1,041	147,995	37,939	Feb 08 07:25 PM
Boyer David W.	Chief Corp. Affairs Officer	Feb 06 '24	Sale	141.96	456	64,734	4,894	Feb 08 07:46 PM
Delaet Ingrid	Chief Regulatory Officer	Feb 01 '24	Sale	139.77	623	87,077	6,865	Feb 02 07:14 PM
GORMAN KEVIN CHARLES	Chief Executive Officer	Jan 31 '24	Sale	140.69	2,707	380,845	502,188	Feb 02 07:21 PM
Boyer David W.	Chief Corp. Affairs Officer	Jan 31 '24	Sale	140.80	2,096	295,115	4,894	Feb 02 07:07 PM
Cooke Julie	Chief Human Resources Officer	Jan 31 '24	Sale	141.29	1,740	245,842	17,263	Feb 02 07:11 PM
Gano Kyle	Chief Business Development Off	Jan 31 '24	Sale	140.70	1,541	216,813	131,635	Feb 02 07:17 PM

Open in Screener

XNCR

Xencor Inc

Jul 26 • 04:00PM ET

21.65

Dollar change +0.38
Percentage change 1.79	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: IJR VTI IWM VB XBI VXF VBK SPSM IBB IJT

Index	RUT	P/E	-	EPS (ttm)	-2.19	Insider Own	2.74%	Shs Outstand	61.00M	Perf Week	13.11%
Market Cap	1.33B	Forward P/E	-	EPS next Y	-2.87	Insider Trans	-7.77%	Shs Float	59.97M	Perf Month	11.43%
Income	-133.36M	PEG	-	EPS next Q	-0.82	Inst Own	103.99%	Short Float	7.98%	Perf Quarter	12.58%
Sales	162.18M	P/S	8.23	EPS this Y	-71.21%	Inst Trans	-2.41%	Short Ratio	7.95	Perf Half Y	9.18%
Book/sh	9.94	P/B	2.18	EPS next Y	19.38%	ROA	-15.80%	Short Interest	4.79M	Perf Year	-10.80%
Cash/sh	8.69	P/C	2.49	EPS next 5Y	-	ROE	-20.58%	52W Range	16.49 - 26.84	Perf YTD	1.98%
Dividend Est.	-	P/FCF	25.35	EPS past 5Y	-9.81%	ROI	-19.28%	52W High	-19.34%	Beta	0.67
Dividend TTM	-	Quick Ratio	7.08	Sales past 5Y	70.11%	Gross Margin	92.42%	52W Low	31.29%	ATR (14)	0.90
Dividend Ex-Date	-	Current Ratio	7.08	EPS Y/Y TTM	6.15%	Oper. Margin	-83.70%	RSI (14)	64.03	Volatility	5.33% 4.13%
Employees	280	Debt/Eq	0.15	Sales Y/Y TTM	65.41%	Profit Margin	-82.23%	Recom	1.46	Target Price	33.75
Option/Short	Yes / Yes	LT Debt/Eq	0.13	EPS Q/Q	-9.33%	Payout	-	Rel Volume	0.71	Prev Close	21.27
Sales Surprise	-44.50%	EPS Surprise	-33.77%	Sales Q/Q	-32.47%	Earnings	May 09 AMC	Avg Volume	602.08K	Price	21.65
SMA20	12.04%	SMA50	3.50%	SMA200	5.09%	Trades		Volume	425,234	Change	1.79%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-16-24	Reiterated	BTIG Research	Buy	$56 → $38
Feb-28-24	Downgrade	Piper Sandler	Overweight → Neutral	$37 → $24
May-19-23	Initiated	BofA Securities	Buy	$42
Dec-06-22	Initiated	Cowen	Outperform
Oct-13-22	Upgrade	Raymond James	Outperform → Strong Buy	$58
Sep-21-22	Initiated	JP Morgan	Overweight	$37
Jul-06-22	Resumed	Canaccord Genuity	Buy	$50
Feb-11-22	Initiated	BMO Capital Markets	Outperform	$54
Jan-21-22	Initiated	SMBC Nikko	Outperform	$60
Dec-15-21	Initiated	H.C. Wainwright	Buy	$61
Oct-15-21	Resumed	BTIG Research	Buy	$56
Feb-24-21	Upgrade	Raymond James	Mkt Perform → Outperform	$58
Mar-04-20	Initiated	Barclays	Underweight	$28
Feb-25-20	Upgrade	Guggenheim	Neutral → Buy	$43
Jan-30-20	Initiated	RBC Capital Mkts	Outperform	$44
Nov-20-19	Resumed	Guggenheim	Neutral
Aug-07-19	Downgrade	Raymond James	Outperform → Mkt Perform
Aug-07-19	Downgrade	Guggenheim	Buy → Neutral
Jun-13-19	Initiated	Mizuho	Buy
Apr-12-19	Initiated	Guggenheim	Buy

Show Previous Ratings

Jun-13-24 08:01AM	Xencor Regains CD20 x CD3 Bispecific T-Cell Engager (Business Wire)
May-10-24 01:45PM	Xencor Inc (XNCR) Q1 2024 Earnings: Misses Revenue and Earnings Estimates (GuruFocus.com)
06:20AM	Wedbush Adjusts Xencor's Price Target to $36 From $34, Keeps Outperform Rating (MT Newswires)
May-09-24 11:54PM	XNCR Stock Earnings: Xencor Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
05:18PM	Xencor: Q1 Earnings Snapshot (Associated Press Finance)
04:09PM	Loading…
04:09PM	Xencor Reports First Quarter 2024 Financial Results (Business Wire)
May-06-24 10:00AM	Xencor (XNCR) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
May-03-24 07:01PM	Insider Sale at Xencor Inc (XNCR): EVP, Chief Development Officer Nancy Valente Sells Shares (GuruFocus.com)
May-02-24 03:31AM	Xencor (XNCR) Moves 14.3% Higher: Will This Strength Last? (Zacks)
Apr-09-24 08:01AM	Xencor Appoints Bart Cornelissen as Chief Financial Officer (Business Wire)
Mar-08-24 05:01PM	Insider Sell: SR. VICE PRESIDENT & CFO John Kuch Sells 4,474 Shares of Xencor Inc (XNCR) (GuruFocus.com)
Mar-07-24 05:00PM	Insider Sell: President & CEO Bassil Dahiyat Sells 12,528 Shares of Xencor Inc (XNCR) (GuruFocus.com)
Feb-28-24 04:01PM	Xencor to Present at Upcoming Investor Conferences (Business Wire) -14.06%
09:35AM	Q4 2023 Xencor Inc Earnings Call (Thomson Reuters StreetEvents)
08:38AM	Xencor, Inc. (NASDAQ:XNCR) Q4 2023 Earnings Call Transcript (Insider Monkey)
05:20PM	Loading…
Feb-27-24 05:20PM	Xencor (XNCR) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:39PM	Xencor Inc (XNCR) Reports Mixed Financial Results for Q4 and Full Year 2023 (GuruFocus.com)
04:26PM	Xencor: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Xencor Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
Feb-20-24 04:31PM	Xencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical Update (Business Wire)
Feb-19-24 03:37AM	Xencor (XNCR) Surges 13.4%: Is This an Indication of Further Gains? (Zacks)
Feb-15-24 10:00AM	Xencor (XNCR) Earnings Expected to Grow: What to Know Ahead of Q4 Release (Zacks) +5.97%
Jan-03-24 04:01PM	Xencor to Present at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
09:55AM	Xencor (XNCR) Soars 6.0%: Is Further Upside Left in the Stock? (Zacks)
Jan-02-24 08:01AM	Dane Leone Joins Xencor as Senior Vice President, Corporate Strategy (Business Wire) +6.03%
Dec-30-23 05:02PM	Insider Sell: Xencor Inc President & CEO Bassil Dahiyat Sells 45,000 Shares (GuruFocus.com)
Nov-21-23 04:01PM	Xencor to Present at the Piper Sandler 35th Annual Healthcare Conference (Business Wire) -6.99%
Nov-09-23 02:19PM	Xencor, Inc. (NASDAQ:XNCR) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 05:21AM	Xencor pulls back from Genentech cancer pact to cut costs, as CytomX drops ex-AbbVie ADC (FierceBiotech.com) -7.01%
Nov-07-23 04:39PM	Xencor: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Loading…
04:01PM	Xencor Sells Portion of Royalties and Milestones from Ultomiris and Monjuvi to OMERS Life Sciences for $215 Million (Business Wire)
04:01PM	Xencor Reports Third Quarter 2023 Financial Results (Business Wire)
Nov-03-23 12:01PM	Xencor Presents Preclinical Data from Multiple XmAb Research Programs at the SITC Annual Meeting (Business Wire) +5.49%
Oct-31-23 04:01PM	Xencor to Host Third Quarter 2023 Financial Results Webcast and Conference Call on November 7, 2023 (Business Wire)
12:00PM	Xencor (XNCR) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Oct-26-23 08:01AM	Xencor Announces Planned Retirement of Chief Financial Officer John Kuch (Business Wire)
Oct-17-23 04:21AM	Jazz (JAZZ) Soars 5.3%: Is Further Upside Left in the Stock? (Zacks)
Sep-27-23 09:01AM	Xencor to Present Multiple Posters at the SITC Annual Meeting (Business Wire)
Sep-19-23 04:01PM	Xencor Appoints Barbara J. Klencke, M.D., to Board of Directors (Business Wire)
Aug-08-23 06:01AM	Analysts Just Published A Bright New Outlook For Xencor, Inc.'s (NASDAQ:XNCR) (Simply Wall St.)
Aug-07-23 04:02PM	Xencor, Inc. (NASDAQ:XNCR) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-03-23 05:15PM	Xencor (XNCR) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:13PM	Xencor: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Xencor Reports Second Quarter 2023 Financial Results (Business Wire)
Jul-27-23 08:01AM	Xencor to Host Second Quarter 2023 Financial Results Webcast and Conference Call on August 3, 2023 (Business Wire)
Jul-03-23 08:38PM	7 Battered Stocks That Could TRIPLE by 2024 (InvestorPlace)
Jun-21-23 08:00PM	XNCR: Lowering target price to $27.00 (Argus Research)
Jun-18-23 10:00AM	Investors in Xencor (NASDAQ:XNCR) have unfortunately lost 34% over the last five years (Simply Wall St.)
May-30-23 06:01PM	Xencor Presents Clinical Results from Phase 1a Study of XmAb®564 at the EULAR 2023 Congress (Business Wire)
May-09-23 01:49PM	Q1 2023 Xencor Inc Earnings Call (Thomson Reuters StreetEvents)
May-08-23 05:15PM	Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:08PM	Xencor: Q1 Earnings Snapshot (AP Finance)
04:01PM	Xencor Reports First Quarter 2023 Financial Results (Business Wire)
May-01-23 04:01PM	Xencor to Host First Quarter 2023 Financial Results Webcast and Conference Call on May 8, 2023 (Business Wire)
Apr-26-23 08:00PM	XNCR: Lowering target price to $28.00 (Argus Research)
08:01AM	Xencor Appoints Nancy Valente, M.D., as Chief Development Officer (Business Wire)
Apr-17-23 01:31PM	Xencor Highlights CD28 Bispecific Antibody Platform at AACR Annual Meeting 2023 (Business Wire)
Apr-09-23 01:19PM	7 Biotech Stocks to Buy for 100% Returns (InvestorPlace)
Mar-14-23 04:31PM	Xencor to Present Preclinical Data from Novel XmAb® CD28 Bispecific Antibody Programs at the American Association for Cancer Research Annual Meeting 2023 (Business Wire)
02:56AM	Strength Seen in Xencor (XNCR): Can Its 5.3% Jump Turn into More Strength? (Zacks)
Feb-28-23 05:10AM	Xencor, Inc. (NASDAQ:XNCR) Analysts Just Trimmed Their Revenue Forecasts By 13% (Simply Wall St.)
Feb-25-23 07:17AM	Xencor Full Year 2022 Earnings: EPS Beats Expectations (Simply Wall St.)
Feb-23-23 05:25PM	Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Xencor Reports Fourth Quarter and Full Year 2022 Financial Results (Business Wire)
Feb-20-23 10:00AM	FibroGen (FGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)
Feb-16-23 04:01PM	Xencor to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023 (Business Wire)
Feb-07-23 04:01PM	Xencor to Present at the SVB Securities Global Biopharma Conference (Business Wire)
Jan-26-23 02:33PM	Why Shares of Zencor Rose This Week (Motley Fool)
Jan-09-23 08:01AM	Xencor Highlights 2023 Corporate Priorities and Provides Portfolio Updates (Business Wire)
Jan-05-23 06:30AM	Caris Life Sciences and Xencor Expand Target Discovery Collaboration for Novel XmAb® Antibody Drug Candidates (PR Newswire)
Jan-04-23 04:01PM	Xencor to Present at the 41st Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-12-22 03:44PM	12 Best Small-Cap Healthcare Stocks To Buy Now (Insider Monkey)
10:00AM	Xencor Presents Data from Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin Lymphoma at the American Society of Hematology Annual Meeting (Business Wire)
Nov-30-22 09:55AM	Does Xencor (XNCR) Have the Potential to Rally 69% as Wall Street Analysts Expect? (Zacks)
Nov-25-22 12:00PM	Xencor (XNCR) Upgraded to Buy: Here's What You Should Know (Zacks)
Nov-10-22 04:01PM	Xencor to Present at Upcoming Investor Conferences (Business Wire)
09:55AM	Can Xencor (XNCR) Climb 75% to Reach the Level Wall Street Analysts Expect? (Zacks)
09:01AM	Xencor Presents Early Clinical Data from Combination Study of Vudalimab and New Data from Multiple Preclinical-stage XmAb® Programs at the SITC Annual Meeting (Business Wire)
Nov-07-22 05:25PM	Xencor (XNCR) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +8.75%
04:01PM	Xencors IL2-Fc Cytokine, XmAb®564, is Well-tolerated and Selectively Expands Regulatory T Cells in Phase 1a Clinical Study (Business Wire)
04:01PM	Xencor Reports Third Quarter 2022 Financial Results (Business Wire)
Nov-03-22 09:01AM	Xencor to Present New Clinical Data from the Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkins Lymphoma at the American Society of Hematology Annual Meeting (Business Wire)
Oct-31-22 04:01PM	Xencor to Host Third Quarter 2022 Financial Results Webcast and Conference Call on November 7, 2022 (Business Wire)
Oct-28-22 11:58AM	Strength Seen in 4D Molecular Therapeutics, Inc. (FDMT): Can Its 16.0% Jump Turn into More Strength? (Zacks)
Oct-14-22 09:41AM	Xencor, Inc. (NASDAQ:XNCR) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future? (Simply Wall St.)
Oct-06-22 08:37PM	Take Opportunities on Days Like Today: Mary Callahan Erdoes Says Now Could Be the Best Time to Invest. Here Are 3 Stocks to Consider (TipRanks)
Oct-05-22 08:01AM	Xencor to Present Seven Posters on Multiple Clinical Trials and Research-stage Programs at the SITC Annual Meeting (Business Wire)
Sep-09-22 08:01AM	Xencor Appoints Nancy Valente, M.D., to Board of Directors (Business Wire)
Aug-29-22 06:35AM	Xencor, Inc.'s (NASDAQ:XNCR) Popularity With Investors Is Under Threat From Overpricing (Simply Wall St.)
Aug-03-22 05:25PM	Xencor (XNCR) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Xencor Reports Second Quarter 2022 Financial Results (Business Wire)
Aug-02-22 06:30AM	Caris Life Sciences and Xencor Enter Target Discovery Collaboration and License Agreement for Novel XmAb® Bispecific Antibodies (PR Newswire)
Aug-01-22 11:31AM	The past three years for Xencor (NASDAQ:XNCR) investors has not been profitable (Simply Wall St.)
Jul-27-22 04:01PM	Xencor to Host Second Quarter 2022 Financial Results Webcast and Conference Call on August 3, 2022 (Business Wire)
Jul-01-22 11:59AM	Shares of Xencor Could Be Bought on a 50% Correction (TheStreet.com) +5.44%
May-26-22 05:01PM	Xencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®104, PD-1 x ICOS Bispecific Antibody, in Advanced Solid Tumors (Business Wire)
May-13-22 09:18AM	7 High-Risk, High-Reward Small-Cap Stocks to Buy Now (InvestorPlace)
May-07-22 09:30AM	Declining Stock and Decent Financials: Is The Market Wrong About Xencor, Inc. (NASDAQ:XNCR)? (Simply Wall St.)
May-06-22 10:24AM	Ironwood (IRWD) Q1 Earnings Miss, Linzess Growth Continues (Zacks)
05:38AM	Zacks.com featured highlights Xencor, Encore Wire and Silvergate Capital (Zacks)

Xencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Desjarlais John R	SR. VICE PRESIDENT & CSO	Jul 10 '24	Option Exercise	10.73	7,785	83,533	200,104	Jul 11 06:41 PM
Desjarlais John R	SR. VICE PRESIDENT & CSO	Jul 09 '24	Option Exercise	10.73	42,215	452,967	228,648	Jul 11 06:41 PM
Desjarlais John R	SR. VICE PRESIDENT & CSO	Jul 09 '24	Sale	18.32	36,329	665,511	192,319	Jul 11 06:41 PM
Valente Nancy	EVP, Chief Development Officer	May 02 '24	Sale	23.58	4,745	111,872	55,115	May 03 04:06 PM
Dahiyat Bassil I	PRESIDENT & CEO	Mar 11 '24	Sale	23.50	2,741	64,418	351,894	Mar 12 04:03 PM
Desjarlais John R	SR. VICE PRESIDENT & CSO	Mar 11 '24	Sale	23.50	1,280	30,082	186,433	Mar 12 04:05 PM
Eckert Celia	SVP, GENERAL COUNSEL	Mar 11 '24	Sale	23.50	850	19,977	45,465	Mar 12 04:06 PM
Kuch John J	SR. VICE PRESIDENT & CFO	Mar 11 '24	Sale	23.50	849	19,953	121,070	Mar 12 04:08 PM
GUSTAFSON KURT A	Director	Mar 06 '24	Option Exercise	10.73	15,000	160,950	20,007	Mar 07 04:10 PM
GUSTAFSON KURT A	Director	Mar 06 '24	Sale	23.18	14,000	324,453	6,007	Mar 07 04:10 PM
Dahiyat Bassil I	PRESIDENT & CEO	Mar 05 '24	Sale	23.43	12,528	293,519	300,097	Mar 07 04:01 PM
Desjarlais John R	SR. VICE PRESIDENT & CSO	Mar 05 '24	Sale	23.43	6,629	155,311	166,989	Mar 07 04:05 PM
Kuch John J	SR. VICE PRESIDENT & CFO	Mar 05 '24	Sale	23.43	4,474	104,821	121,919	Mar 07 04:07 PM
Eckert Celia	SVP, GENERAL COUNSEL	Mar 05 '24	Sale	23.43	3,892	91,186	33,226	Mar 07 04:03 PM
Desjarlais John R	SR. VICE PRESIDENT & CSO	Feb 14 '24	Option Exercise	11.05	11,943	131,970	173,618	Feb 16 04:06 PM
Desjarlais John R	SR. VICE PRESIDENT & CSO	Feb 13 '24	Option Exercise	11.05	68,057	752,030	215,783	Feb 14 02:23 PM
GORMAN KEVIN CHARLES	Director	Feb 13 '24	Buy	19.12	53	1,013	5,060	Feb 15 04:02 PM
Desjarlais John R	SR. VICE PRESIDENT & CSO	Feb 13 '24	Sale	19.38	54,108	1,048,743	161,675	Feb 14 02:23 PM
Dahiyat Bassil I	PRESIDENT & CEO	Dec 29 '23	Option Exercise	11.05	65,001	718,261	357,929	Dec 29 04:24 PM
Dahiyat Bassil I	PRESIDENT & CEO	Dec 29 '23	Sale	20.93	45,000	941,670	312,929	Dec 29 04:24 PM

NBIX

Neurocrine Biosciences, Inc.

XNCR

Xencor Inc

Upgrade your FINVIZ experience